The Pharmaceutical Journal
Vol 274 No 7352 p670
4 June 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

DTB challenges first-line use of certain anti-hypertensives

First-line use of angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists in patients with type 2 diabetes who also have microalbuminuria has been called into question by the Drug and Therapeutics Bulletin.

DTB suggests there is only limited evidence to support this approach, pointing out that most patients with type 2 diabetes and high blood pressure will require combination drug treatment. “This will usually include an ACE inhibitor or angiotensin-II receptor antagonist,” the review concludes (2005;43:41).